4/A: Monopar Therapeutics Director Sells Shares
Insider Transaction (Form 4/A)
Raymond Anderson, a Director of Monopar Therapeutics, sold 3,142 shares of common stock on August 25, 2026.
Summary
- Option exercise/conversion: acquired 1,402 Common Stock at $30.00 ($42,060) on August 25, 2026; holds 6,775 after (Direct).
- Option exercise/conversion: acquired 1,740 Common Stock at $30.00 ($52,200) on August 25, 2026; holds 8,515 after (Direct).
- Open-market sale: disposed of 694 Common Stock at $110.04 ($76,368) on August 25, 2026; holds 7,821 after (Direct).
- Open-market sale: disposed of 646 Common Stock at $111.07 ($71,751) on August 25, 2026; holds 7,175 after (Direct).
- Open-market sale: disposed of 1,802 Common Stock at $113.05 ($203,716) on August 25, 2026; holds 5,373 after (Direct).
- Option exercise/conversion: acquired 1,402 Stock Option on August 25, 2026; holds 2,803 after (Direct).
- Option exercise/conversion: acquired 1,740 Stock Option on August 25, 2026; holds 3,480 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $351,835 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Raymond Anderson — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-25 | Option exercise/conversion | Common Stock | 1,402 | $30 | $42.1K | 6,775 |
| 2026-08-25 | Option exercise/conversion | Common Stock | 1,740 | $30 | $52.2K | 8,515 |
| 2026-08-25 | Open-market sale | Common Stock | 694 | $110 | $76.4K | 7,821 |
| 2026-08-25 | Open-market sale | Common Stock | 646 | $111 | $71.8K | 7,175 |
| 2026-08-25 | Open-market sale | Common Stock | 1,802 | $113 | $203.7K | 5,373 |
| 2026-08-25 | Option exercise/conversion | Stock Option | 1,402 | — | — | 2,803 |
| 2026-08-25 | Option exercise/conversion | Stock Option | 1,740 | — | — | 3,480 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-25 | Option exercise/conversion (1,402 shares) |
| 2026-08-25 | Option exercise/conversion (1,740 shares) |
| 2026-08-25 | Open-market sale (694 shares) |
| 2026-08-25 | Open-market sale (646 shares) |
| 2026-08-25 | Open-market sale (1,802 shares) |
| 2026-08-25 | Option exercise/conversion (1,402 shares) |
| 2026-08-25 | Option exercise/conversion (1,740 shares) |
Keywords
insider transaction, Form 4/A, MNPR, Monopar Therapeutics, bearish, Raymond Anderson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.